Unknown

Dataset Information

0

Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms.

ABSTRACT:

SUBMITTER: Halpern AB 

PROVIDER: S-EPMC6442971 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms.

Halpern Anna B AB   Othus Megan M   Huebner Emily M EM   Scott Bart L BL   Hendrie Paul C PC   Percival Mary-Elizabeth M MM   Becker Pamela S PS   Smith Heather A HA   Oehler Vivian G VG   Orozco Johnnie J JJ   Cassaday Ryan D RD   Gardner Kelda M KM   Chen Tara L TL   Buckley Sarah A SA   Orlowski Kaysey F KF   Anwar Asma A   Estey Elihu H EH   Walter Roland B RB  

Haematologica 20181108 4

Similar Datasets

Unknown Phase 1 trial of venetoclax with cladribine, cytarabine, G-CSF, and mitoxantrone for AML and high-grade myeloid neoplasm.
| S-EPMC12171542 | biostudies-literature
Unknown Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML.
| S-EPMC10463192 | biostudies-literature
Unknown Reassessing the role of high dose cytarabine and mitoxantrone in relapsed/refractory acute myeloid leukemia.
| S-EPMC7289527 | biostudies-literature
Unknown A multi-institutional comparison of mitoxantrone, etoposide, and cytarabine vs high-dose cytarabine and mitoxantrone therapy for patients with relapsed or refractory acute myeloid leukemia.
| S-EPMC9150866 | biostudies-literature
Unknown Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms.
| S-EPMC6192860 | biostudies-literature
Unknown A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia.
| S-EPMC5932089 | biostudies-literature
Unknown Randomized phase 1 study of sequential ("primed") vs. concurrent decitabine in combination with cladribine, cytarabine, G-CSF, and mitoxantrone (CLAG-M) in adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) or other high-grade myeloid neoplasm.
| S-EPMC7384960 | biostudies-literature
Unknown Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study.
| S-EPMC5709258 | biostudies-literature
Unknown Phase 1/2 Trial of CLAG-M with Dose-Escalated Mitoxantrone in Combination with Fractionated-Dose Gemtuzumab Ozogamicin for Newly Diagnosed Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms.
| S-EPMC9221325 | biostudies-literature
Unknown CLAG-M with dose-escalated mitoxantrone for adults with acute myeloid leukemia.
| S-EPMC6290957 | biostudies-literature